Journal
MEDICINE
Volume 100, Issue 6, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000024544
Keywords
aspirin; COVID-19; infections; prognosis; SARS-Cov-2
Categories
Funding
- National Nature Science Foundation of China [81403163, 81402404]
Ask authors/readers for more resources
In a study involving adults infected with SARS-Cov-2, it was found that patients using low-dose aspirin (100 mg/day) had significantly lower 30-day and 60-day mortality rates compared to those not using aspirin, although there was no significant difference in viral duration between the two groups.
To clarify the effect of aspirin on mortality and viral duration in adults infected with respiratory syndrome coronavirus 2 (SARS-Cov-2). After propensity score-matched (PSM) case-control analyses 24 pairs of patients were enrolled and followed up for 2 months. Both 30-day and 60-day mortality in the aspirin group were significantly lower than that in the non-aspirin group (P = .021 and P = .030, respectively). The viral duration time between the 2 groups was not significantly different (P = .942). Among adults (with hypertension, cardiovascular diseases) infected with SARS-Cov-2, low-dose aspirin medication (100 mg/day) was associated with lower risk of mortality compared with non-aspirin users.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available